Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$2.16−0.41 (-15.95%)
Close on Nov 11, 2026Market cap $26.98MP/E –Yield –
Aligos Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Aligos Therapeutics's enterprise value was -$16.91M on Nov 11, 2026, against -$40.15M a year earlier. Over the last 5 years it ranged from -$155.43M to $263.10M, with a median of -$61.35M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$16.91M | – |
| 2025 | Dec 31, 2025 | -$41.75M | -172.5% |
| 2024 | Dec 31, 2024 | $57.56M | – |
| 2023 | Dec 29, 2023 | -$41.51M | – |
| 2022 | Dec 30, 2022 | -$101.50M | -138.6% |
| 2021 | Dec 31, 2021 | $263.10M | +222.1% |
| 2020 | Dec 31, 2020 | $81.68M | – |
See a number that looks wrong?